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Research
AbstrACt
Objectives Previous studies indicate frailty to be 
associated with poor outcomes following transcatheter 
aortic valve implantation (TAVI), but there is limited 
evidence from multicentre registries. The aim was to 
investigate the independent association of frailty with TAVI 
outcomes, and the prognostic utility of adding frailty into 
existing clinical prediction models (CPMs).
Design The UK TAVI registry incorporated three frailty 
measures since 2013: Canadian Study of Health and 
Ageing, KATZ and poor mobility. We investigated the 
associations between these frailty measures with short-
term and long-term outcomes, using logistic regression to 
estimate multivariable adjusted ORs, and Cox proportional 
hazards models to explore long-term survival. We 
compared the predictive performance of existing TAVI 
CPMs before and after updating them to include each 
frailty measure.
setting All patients who underwent a TAVI procedure in 
England or Wales between 2013 and 2014.
Participants 2624 TAVI procedures were analysed in this 
study.
Primary and secondary outcomes The primary 
endpoints in this study were 30-day mortality and long-
term survival. The Valve Academic Research Consortium 
(VARC)-2 composite early safety endpoint was considered 
as a secondary outcome.
results KATZ <6 (OR 2.10, 95% CI 1.39 to 3.15) and 
poor mobility (OR 2.15, 95% CI 1.41 to 3.28) predicted 
30-day mortality after multivariable adjustment. All 
frailty measures were associated with increased 
odds of the VARC-2 composite early safety endpoint. 
We observed a significant increase in the area under 
the receiver operating characteristic curves by 
approximately 5% after adding KATZ <6 or poor mobility 
into the TAVI CPMs. Risk stratification agreement was 
significantly improved by the addition of each frailty 
measure, with an increase in intraclass correlation 
coefficient of between 0.15 and 0.31.
Conclusion Frailty was associated with worse outcomes 
following TAVI, and incorporating frailty metrics 
significantly improved the predictive performance of 
existing CPMs. Physician-estimated frailty measures could 
aid TAVI risk stratification, until more objective scales are 
routinely collected.
IntrODuCtIOn 
Transcatheter aortic valve implantation 
(TAVI) has emerged as an effective treatment 
strategy for patients with aortic stenosis who 
are intermediate-to-high operative risk.1–3 
To this end, surgical clinical prediction 
models (CPMs), such as the EuroSCORE 
or the Society of Thoractic Surgeons (STS) 
model, have previously been used to estimate 
risk, but TAVI-specific CPMs are emerging 
from national registries: examples include the 
FRANCE-2 model,4 the OBSERVANT model5 
and the American College of Cardiology 
(ACC) Transcatheter Valve Therapy model.6 
However, these models do not usually incor-
porate measures of frailty and disability into 
geriatric prescreening risk assessment.
strengths and limitations of this study
 ► An analysis of the association between three frail-
ty measures and clinical outcomes following tran-
scatheter aortic valve implantation (TAVI).
 ► The study used data from the UK TAVI registry, in-
cluding all consecutive patients who underwent TAVI 
in UK between 2013 and 2014.
 ► A large, contemporary study, which investigated the 
impact of frailty on outcomes and mortality predic-
tion post-TAVI from a national perspective.
 ► Only three subjective frailty measures were avail-
able, with objective frailty tests not recorded.
 ► This retrospective analysis could not compare out-
comes across frailty groups in patients with un-
treated aortic stenosis, or those undergoing surgical 
replacement.
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Frailty is an emerging concept in clinical science and 
is defined as an age-related decline in the resilience to 
stressors caused by deterioration in multiple physiolog-
ical systems.7 Consequently, there is a growing evidence 
base of associations between frailty and poor outcomes 
after TAVI.8–13 Indeed, patient’s frailty, dependencies in 
activities of daily living (ADL) and cognitive function are 
increasingly being considered in the decision-making 
process for TAVI eligibility.14 However, measures of frailty 
are rarely incorporated into many of the currently avail-
able CPMs, which has potentially contributed to the 
moderate predictive performance of such models outside 
their development datasets.15–17 The recent recording of 
measures relating to frailty/disability in national cohorts 
presents novel opportunities to incorporate them into 
future iterations of existing TAVI CPMs.
Therefore, the aim was to investigate the effect of frailty 
and disability on mortality and morbidity in a national 
TAVI cohort and to examine the prognostic utility of 
adding frailty/disability into existing TAVI CPMs.
MethODs
uK tAVI registry
The UK TAVI registry prospectively collects 95 variables 
(including patient demographics, risk factors for inter-
vention and within-hospital adverse outcomes), for every 
TAVI procedure conducted in the UK.18 This analysis 
used data from patients in England and Wales, for whom 
all-cause mortality was linked from the Office for National 
Statistics. The study period for this analysis was January 
2013 to December 2014, corresponding to the time in 
which the UK registry recorded three variables that related 
to frailty/disability. Specifically, the registry recorded the 
Canadian Study of Health and Ageing (CSHA)-estimated 
frailty scale,19 KATZ ADL dependency20 and a physician-es-
timated poor mobility (as defined in the EuroSCORE II 
model21). Frailty groups were defined separately across 
the three measures with the full definitions of each group 
given in table 1. Dichotomising CSHA and KATZ scores 
into two categories was based on the empirical median 
value (CSHA=‘apparently vulnerable’ and KATZ=6), and 
on the original publication of CSHA.19 Additionally, for 
this analysis, we defined a composite score to incorporate 
information from all three of the measures, with the defi-
nition given in table 1.
study endpoints
The primary endpoints in this study were 30-day mortality 
and long-term survival. As a secondary endpoint, we 
investigated the Valve Academic Research Consortium 
(VARC)-2 composite early safety endpoint, which is 
defined as a failure in any of the following outcomes 
by 30 days: all-cause mortality, stroke, life-threatening 
bleeding, stage 2/3 acute kidney injury, coronary artery 
obstruction requiring intervention, major vascular 
complications or valve-related dysfunction requiring a 
repeat procedure.14
Table 1 Frailty grouping definitions by each frailty/disability measure
Frailty/disability 
measure Scoring system Frailty definition used in this analysis
CSHA* A physician-estimated frailty score, based on the 
following options: (1) very fit, (2) well,; (3) well with 
treated comorbid disease, (4) apparently vulnerable, 
(5) mildly frail with limited dependence for activities 
of daily living (ADL), (6) moderately frail requiring 
help with ADL, (7) severely frail being completely 
dependent.
CSHA options of 5–7 were used to define 
CSHA frail patients; options 1–4 were 
classed as CSHA non-frail.
KATZ* 0–6 points scale assessing dependency in the 
following ADL: (1) bathing, (2) dressing, (3) toileting, (4) 
transferring, (5) continence, (6) Feeding.
Any patient with a KATZ score <6 points 
compared with those with KATZ=6.
Poor mobility A physician-estimated indication of any severe 
impairment of mobility that is secondary to 
musculoskeletal or neurological dysfunction.
Any patient defined as having poor mobility 
compared with those defined as having 
normal mobility.
Composite score Combination of CSHA, KATZ and poor mobility. Defined as the following:
(1) Non-frail if a patient is estimated as not 
frail by CSHA, KATZ and poor mobility.
(2) Moderately frail if a patient is estimated 
as frail by at least one (but not all) 
considered frailty measures.
(3) Severely frail if a patient is classed as 
frail across all three of CSHA, KATZ and 
poor mobility.
*Dichotomising of CSHA and KATZ into two groups was based on the median level observed in the TAVI registry (see online supplementary 
figures 1 and 2 for the distribution of these scores).
CSHA, Canadian Study of Health and Ageing; TAVI, transcatheter aortic valve implantation.
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statistical analysis
Every variable with missing data was imputed using 
multiple imputation that generated 10 imputed data-
sets.22 The imputation model for each variable included 
the majority of other variables in the UK TAVI registry 
and all considered endpoints.23 Imputed frailty measures 
and outcomes were not used, and instead were returned 
to the original (missing) values.24 Subsequently, patients 
missing data on CSHA, KATZ, poor mobility and/
or missing life status were removed from the analysis; 
patients with missing VARC-2 composite early safety were 
only removed from the analysis of that outcome. All anal-
yses were undertaken in each imputed dataset separately, 
with the results pooled according to Rubin’s rules.22
For exploratory analysis, we obtained spatial maps of 
England at a National Health Service (NHS) regional 
level (a high-level geographical structure partitioning 
England into 13 regions) and of Wales, from the Office 
for National Statistics. By linking the clinical commission 
group of each patient to the corresponding NHS region, 
we calculated the proportion of frail patients in the study 
population across England and Wales.
Odds Ratios (ORs) for binary endpoints were esti-
mated using logistic regression, with both unadjusted and 
adjusted ORs reported. Multivariable models adjusted 
for the following variables: total centre volume, age, sex, 
diabetes status, smoking status, creatinine, renal failure, 
previous myocardial infarction, pulmonary disease, 
neurological disease, extracardiac arteriopathy, calci-
fication of ascending aorta, atrial fibrillation/flutter, 
previous cardiac surgery, previous percutaneous coro-
nary intervention, height, weight, critical preoperative 
status, Canadian Cardiovascular Society grading class 4, 
New York Heart Association (NYHA) class ≥III, aortic 
valve area and peak gradient, left ventricular ejection 
fraction (LVEF) <50%, one or more diseases vessels, left 
main stem disease, non-elective procedure indication and 
non-transfemoral access indication.
Long-term survival was assessed non-parametrically 
using Kaplan-Meier plots and strata were compared using 
the log-rank test. Multivariable adjustment was performed 
using Cox proportional hazards models, using the same 
variables as above to adjust the frailty indication hazard 
ratio (HR) for measured confounding. To account for 
non-proportional hazards, time was split into strata of 
0–180 days, 180–365 days and >365 days, with frailty-indi-
cation-by-time-indicator interactions included in the Cox 
proportional hazards models.
The effect on predictive performance of adding 
CSHA-estimated frailty, KATZ ADL dependency or physi-
cian-estimated poor mobility into the existing TAVI CPMs 
(FRANCE-2, OBSERVANT and ACC) was considered 
using model updating techniques.25–27 Mathematical 
details of model updating techniques are given in the 
supplementary methods. In short, CSHA, KATZ and poor 
mobility were added (both separately and sequentially for 
each measure) into an existing CPM by fitting a logistic 
regression model of 30-day mortality, with both the linear 
predictor of the considered TAVI CPM and at least one 
of the frailty measures as covariates. The likelihood ratio 
test (LRT) was used to test for significant improvement in 
model fit before and after model updating. Additionally, 
the area under the receiver operating characteristic curve 
(AUC) was calculated for each model and compared 
using a DeLong comparison.28 Finally, intraclass correla-
tion coefficient (ICC) estimates and their 95% CIs were 
calculated based on an absolute-agreement, two-way 
random effects model to indicate the risk-prediction 
agreement between the TAVI CPMs both before and after 
the addition of CSHA, KATZ or poor mobility.
R V.3.4.029 was used for all statistical analyses. Graph-
ical plots were made using the ggplot2 package30 and the 
mice package was used for the multiple imputation.31
Patient and public involvement
No patients were involved in the design or conducting of 
this study.
results
Between January 2013 and December 2014, n=3073 
patients underwent a TAVI procedure in England and 
Wales. After excluding 104 patients with missing life status 
and 345 patients with any missing frailty measure, 2624 
patients were analysed in this study. Due to the relative 
high proportion of exclusions (14.6%), we examined 
baseline characteristics of included patients compared 
with those excluded (online supplementary table 1). 
Most of the baseline characteristics were similar between 
the study group and the excluded group, with the excep-
tion of access route, proportion of calcified aorta and 
NYHA ≥III.
A total of 1043 patients (39.7%) had CSHA-estimated 
frailty (online supplementary figure 1), 846 patients 
(32.2%) had ADL dependency (KATZ <6) (online supple-
mentary figure 2) and 591 patients (22.5%) had physi-
cian-estimated poor mobility. Figure 1 shows a Venn 
diagram of the overlap in classification across the three 
measures. The central segment of the Venn diagram 
(n=297) is the group defined as ‘severely frail’ by the 
composite score, with the other segments (n=1169) 
showing the ‘moderately frail’ group. The disagreement 
in figure 1 may relate to both the relative imprecision and 
subjectivity of each frailty measure and that the different 
measures assess disparate aspects of frailty.
Baseline characteristics and the proportion of 
missing data for the whole cohort are presented in 
table 2. Comparisons of baseline characteristics across 
CSHA-estimated frailty, KATZ ADL dependency and 
physician-estimated poor mobility groups are given in 
online supplementary tables 2–4, respectively. CSHA-es-
timated frail patients were more likely female (p<0.001), 
with higher proportions of NYHA ≥III (p<0.001), 
LVEF <50% (p=0.001) and non-elective procedures 
(p<0.001), but with lower numbers of CSHA-estimated 
frail patients having a previous cardiac surgery (p<0.001). 
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Similar differences were observed between KATZ ADL 
dependency (online supplementary table 3) and between 
physician-estimated poor mobility groups (online supple-
mentary table 4).
There was large spatial heterogeneity in the proportion 
of TAVI procedures conducted in patients estimated as 
having poor mobility, KATZ <6 or CSHA-estimated frailty 
(online supplementary figure 3). For example, propor-
tions of physician-estimated poor mobility patients across 
NHS regions ranged from 6.5% to 42.7%; NHS England 
North (Lancashire and Greater Manchester) had the 
highest proportion of patients with KATZ <6 and CSHA-es-
timated frailty, while NHS England South (Wessex) had 
the highest proportion of physician-estimated poor 
mobility patients.
Frailty and post-tAVI outcomes
Incremental increases in components of CSHA and KATZ 
were associated with increased crude 30-day mortality 
rates (online supplementary figures 2 and 3). Specifically, 
CSHA-estimated frail patients had higher crude 30-day 
mortality, but this was not significant after multivariable 
adjustment (table 3). In contrast, physician-estimated 
poor mobility and KATZ <6 were significantly associated 
with increased odds of 30-day mortality after multivariable 
adjustment. All three of the considered frailty measures 
were independently associated with increased VARC-2 
composite early safety endpoint (table 3). Similarly, those 
defined as frail across all three of CSHA, KATZ and poor 
mobility (ie, severely frail within the composite score) 
had significantly higher multivariable adjusted odds of 
30-day mortality and composite early safety compared 
with patients defined as non-frail by the composite score 
(online supplementary table 5).
Figure 1 Venn diagram showing the overlap in the different 
definitions of frailty/disability across CSHA-estimated frailty, 
KATZ <6 and physician-estimated poor mobility; the sizes 
of each segment are proportional to the segment sample 
sizes. CSHA, Canadian Study of Health and Ageing.
Table 2 Baseline characteristics and number of missing 
data within the whole cohort
Variable
Whole cohort 
(n=2624) Missing, n (%)
Age, mean (SD) 81.2 (7.58) 0 (0.00)
Female, n (%) 1192 (45.4) 1 (0.04)
Diabetic, n (%) 641 (24.4) 2 (0.08)
Smoker, n (%) 1316 (50.2) 45 (1.71)
Creatinine, mean (SD) 110.9 (60.5) 6 (0.23)
Renal failure*, n (%) 143 (5.45) 10 (0.38)
Previous MI, n (%) 558 (21.3) 2 (0.08)
Pulmonary disease, n (%) 791 (30.1) 3 (0.11)
Neurological disease, n (%) 441 (16.8) 1 (0.04)
Extracardiac arteriopathy, 
n (%)
555 (21.2) 5 (0.19)
Calcification of ascending 
aorta, % (n)
378 (14.4) 22 (0.84)
Atrial fibrillation, n (%) 700 (26.7) 23 (0.88)
Previous cardiac surgery, 
n (%)
799 (30.4) 5 (0.19)
Previous PCI, n (%) 524 (20.0) 2 (0.08)
Height, mean (SD) 1.64 (0.10) 19 (0.72)
Weight, mean (SD) 75.0 (17.1) 18 (0.69)
CCS class 4, n (%) 24 (0.91) 3 (0.11)
NYHA ≥III, n (%) 1985 (75.6) 6 (0.23)
Aortic valve area, mean (SD) 0.69 (0.23) 147 (5.60)
Aortic valve peak gradient, 
mean (SD)
71.2 (26.2) 129 (4.92)
LVEF <50%, n (%) 948 (36.1) 12 (0.46)
One or more diseased 
vessels, n (%)
1058 (40.3) 47 (1.79)
Left main stem disease, n 
(%)
103 (3.93) 75 (2.86)
Non-elective procedure, n 
(%)
365 (13.9) 2 (0.08)
Access site
  Transfemoral, n (%) 2127 (81.1) 3 (0.11)
  Transapical, n (%) 249 (9.49) 3 (0.11)
  Subclavian, n (%) 85 (3.24) 3 (0.11)
  Other, n (%) 160 (6.10) 3 (0.11)
*Defined as creatinine >200 µmol/L or dialysis for renal failure.
CCS, Canadian Cardiovascular Society; LVEF, left ventricular 
ejection fraction; MI, myocardial Infarction; NYHA, New York Heart 
Association; PCI, percutaneous coronary intervention.
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Overall survival was 95.9%, 85.2% and 76.3% at 30 days, 
1 year and 2 years, respectively. Survival was signifi-
cantly worse for patients with CSHA-estimated frailty 
(p<0.0001), KATZ <6 (p<0.0001), physician-estimated 
poor mobility (p<0.001), and across the composite frailty 
groups (p<0.0001) (figure 2). The multivariable time-de-
pendent Cox proportional hazards models indicated that 
hazards of mortality were significantly higher for those 
with KATZ <6 or physician-estimated poor mobility within 
1-year post-TAVI (table 4); after 1 year, multivariable 
Table 3 Short-term outcomes across CSHA-estimated frailty, KATZ ADL dependency and physician-estimated poor mobility 
groups
Outcome
CSHA-estimated frail 
(n=1043)
CSHA-estimated non-frail 
(n=1581)
Univariable OR 
(95% CI)*
Multivariable OR 
(95% CI)*
30-day mortality 57/1043 (5.47%) 51/1581 (3.23%) 1.73 (1.18 to 2.55) 1.46 (0.96 to 2.23)
Early safety 187/1014 (18.44%) 190/1540 (12.34%) 1.61 (1.29 to 2.00) 1.45 (1.14 to 1.84)
Outcome KATZ <6 (n=846) KATZ=6 (n=1778)
Univariable OR 
(95% CI)*
Multivariable OR 
(95% CI)*
30-day mortality 58/846 (6.86%) 50/1778 (2.81%) 2.54 (1.73 to3.75) 2.10 (1.39 to3.15)
Early safety 150/827 (18.14%) 227/1727 (13.14%) 1.46 (1.17 to 1.83) 1.28 (1.01 to 1.63)
Outcome Poor mobility (n=591) Normal mobility (n=2033)
Univariable OR 
(95% CI)*
Multivariable OR 
(95% CI)*
30-day mortality 46/591 (7.78%) 62/2033 (3.05%) 2.68 (1.81 to 3.98) 2.15 (1.41 to 3.28)
Early safety 116/571 (20.32%) 261/1983 (13.16%) 1.68 (1.32 to 2.14) 1.45 (1.12 to 1.88)
*Bold items indicate significant results.
ADL, activities of daily living; CSHA, Canadian Study of Health and Ageing. 
Figure 2 Kaplan-Meier plots across CSHA-estimated frailty (top-left), KATZ activities of daily living dependency (top-right), 
physician-estimated poor mobility (bottom-left) and the composite frailty score (bottom-right). Definitions are described in 
table 1. CSHA, Canadian Study of Health and Ageing; TAVI, transcatheter aortic valve implantation.
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adjusted hazards were not significantly different for 
these measures. CSHA-estimated frailty had significantly 
increased hazards of mortality 0–180 days and >365 days 
post-TAVI, but hazards were not significantly different 
between these time windows. Quantitatively, similar results 
were found across the composite score frailty groups.
Addition of frailty in tAVI CPMs
Table 5 gives the discrimination of each TAVI CPM for 
predicting 30-day mortality both before and after the 
addition of each frailty measure. The LRT indicated a 
significant improvement in model fit by adding CSHA-es-
timated frailty into the FRANCE-2 model (p=0.037), 
the OBSERVANT model (p=0.020) and the ACC model 
(p=0.048). Adding KATZ <6 into the TAVI models signifi-
cantly improved the AUC of both the FRANCE-2 CPM 
(p=0.047) and the OBSERVANT CPM (p=0.007), with 
the LRT indicating a significant improvement in model 
fit for all three TAVI CPMs (p<0.001). Equally, physi-
cian-estimated poor mobility significantly improved the 
fit of all three models (LRT p<0.001) and significantly 
increased the AUC of the OBSERVANT (p=0.006) and 
the ACC (p=0.030) CPMs by 7% and 5%, respectively. A 
forward stepwise selection of all three measures resulted 
in KATZ <6 and physician-estimated poor mobility being 
added into each of the existing TAVI CPMs (table 5), that 
is, CSHA-estimated frailty did not significantly improve 
the predictive performance of the existing TAVI models 
after inclusion of KATZ <6 and physician-estimated poor 
mobility.
Finally, the absolute-agreement ICC between the orig-
inal versions of each TAVI CPM was 0.39 (95% CI 0.27 to 
0.49), which increased to 0.65 (95% CI 0.63 to 0.67), 0.78 
(95% CI 0.76 to 0.79) and 0.81 (95% CI 0.79 to 0.82) on 
adding CSHA-estimated frailty, KATZ <6 or physician-esti-
mated poor mobility, respectively. Thus, the patient-level 
agreement in risk prediction between the three TAVI 
CPMs was significantly improved after adding any of 
CSHA, KATZ or poor mobility into the models.
DIsCussIOn
The findings from this study can be summarised as follows: 
(1) KATZ <6 and physician-estimated poor mobility were 
independently associated with increased 30-day mortality, 
and all three considered frailty measures were associated 
with increased VARC-2 composite early safety; (2) patients 
with KATZ <6 and physician-estimated poor mortality had 
significantly worse survival up to 1-year post-TAVI; (3) the 
addition of KATZ and physician-estimated poor mobility 
into existing TAVI CPMs significantly improved the 
Table 4 Time-dependent Cox proportional hazards models 
per frailty indicator
Frailty-by-time 
interaction
Univariable HR 
(95% CI)*
Multivariable HR 
(95% CI)*
CSHA-estimated frail
  0–180 days 1.56 (1.22 to 1.98) 1.29 (1.00 to 1.66)
  180–365 days 1.63 (1.12 to 2.38) 1.37 (0.94 to 2.01)
  >365 days 1.85 (1.32 to 2.60) 1.61 (1.14 to 2.29)
KATZ <6
  0–180 days 1.71 (1.34 to 2.18) 1.55 (1.21 to 1.99)
  180–365 days 1.86 (1.28 to 2.71) 1.74 (1.19 to 2.55)
  >365 days 1.25 (0.88 to 1.78) 1.23 (0.86 to 1.75)
Physician-estimated poor mobility
  0–180 days 1.74 (1.34 to 2.25) 1.50 (1.15 to 1.96)
  180–365 days 2.06 (1.39 to 3.06) 1.84 (1.24 to 2.75)
  >365 days 1.50 (1.03 to 2.20) 1.36 (0.92 to 2.00)
*Bold items indicate significant results.
CSHA, Canadian Study of Health and Ageing.
Table 5 Discrimination of each TAVI CPM at predicting 
30-day mortality before and after the addition of each frailty 
measure
Model AUC (95% CI) P values*
FRANCE-2
  Original 0.62 (0.57 to 0.68) N/A
  Updated with CSHA only 0.64 (0.58 to 0.69) 0.412
  Updated with KATZ only 0.67 (0.61 to 0.72) 0.047
  Updated with poor 
mobility only
0.67 (0.62 to 0.72) 0.058
  Updated with stepwise 
selection†
0.68 (0.63 to 0.73) 0.025
Observant
  Original 0.56 (0.50 to 0.62) N/A
  Updated with CSHA only 0.59 (0.53 to 0.65) 0.129
  Updated with KATZ only 0.62 (0.56 to 0.68) 0.007
  Updated with poor 
mobility only
0.63 (0.57 to 0.69) 0.006
  Updated with stepwise 
selection†
0.64 (0.58 to 0.71) 0.002
ACC
  Original 0.63 (0.58 to 0.68) N/A
  Updated with CSHA only 0.64 (0.59 to 0.69) 0.605
  Updated with KATZ only 0.67 (0.61 to 0.72) 0.069
  Updated with poor 
mobility only
0.68 (0.63 to 0.73) 0.030
  Updated with stepwise 
selection†
0.68 (0.63 to 0.74) 0.036
*The DeLong p value compares the AUC of predicting 30-day 
mortality using the original TAVI CPM with that using each 
corresponding updated version.
†Forward selection across the three frailty measures resulted in 
KATZ <6 and physician-estimated poor mobility being added into 
each existing TAVI CPM.
ACC, American College of Cardiology; AUC, area under the curve; 
CPM, clinical prediction model; CSHA, Canadian Study of Health 
and Ageing; N/a, not applicable; TAVI, transcatheter aortic valve 
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discrimination and patient-level risk-stratification agree-
ment of the models.
Frailty and clinical outcomes following tAVI
Given that frailty is an indicator of general health status 
and vulnerability among elderly patients,7 it is naturally 
under study in the TAVI field. The current study supports 
and expands the findings from previous studies that 
have shown associations between frailty and poor TAVI 
outcomes.8–13 32–34 For instance, a previous analysis of a 
single UK centre showed that poor mobility strongly 
predicted survival following TAVI10; the current study 
supports this finding at the national level, in showing that 
the odds of 30-day mortality in those with physician-esti-
mated poor mobility were 2.15 times higher compared 
with normal mobility. Similarly, a multicentre investiga-
tion of the Japanese registry found that a semiquantitative 
Clinical Frailty Scale was associated with increased 30-day 
and 1-year mortality.12 Together, the current and previous 
results suggest that frailty/disability is an indicator of 
worse outcomes post-TAVI, despite the heterogeneity in 
frailty measures used across the existing evidence base. 
AHA/ACC guidelines currently indicate that KATZ, gait 
speed and grip strength should be used in the assessment 
of surgical risk,35 with the emerging data suggesting that 
similar recommendations should be made for TAVI risk 
assessment and prediction.
However, implementing this emerging evidence may 
prove difficult without consensus regarding the most 
clinically useful measure of frailty in TAVI patients. By 
comparing the predictive performance of seven different 
frailty scales, Afilalo et al recently recommended that 
the ‘Essential Frailty Toolset’, which includes multiple 
domains of frailty (motor skills, cognition and nutri-
tional/physiological factors), be used in TAVI patients.11 
Data on such frailty domains were unavailable for the 
current study, with the three subjective measures collected 
within the UK TAVI registry mainly using measurements 
of ADL. Nonetheless, it is conceivable that assessment of 
ADL (eg, KATZ) could provide a simple mechanism of 
informing part of the risk assessment process for TAVI, 
until more objective frailty scales are routinely collected. 
For instance, a previous multicentre study by Alfredsson 
et al showed that an objective measure of gait speed was 
associated with 30-day mortality following TAVI,32 but 
such measures are rarely recorded in national registries, 
which would currently limit their use to aid risk predic-
tion/stratification in TAVI patients.
Moreover, outcomes after TAVI should consider both 
mortality and quality of life in the context of the elderly 
patients who predominantly undergo TAVI. Previous 
work has shown associations between frailty and quality 
of life36 and a contemporary TAVI CPM that was derived 
to predict poor outcome (defined as mortality and/
or reduced quality of life) included measures of frailty, 
functional status and cognitive decline.37 38 Within the 
current study, indicators of quality of life were not avail-
able, which should be noted as a limitation of the study. 
Consequently, further studies are needed to investigate 
the effect of frailty on endpoints such as quality of life 
or hospital readmission, which are increasingly used as a 
measure of futility in TAVI patients.
Prognostic utility of frailty
Prognostic risk prediction for TAVI is an ongoing research 
area, with existing TAVI CPMs reporting only moderate 
performance when validated.4–6 16 We found that adding 
indicators of dependency in ADL (KATZ <6) or physi-
cian-estimated poor mobility significantly improved the 
predictive performance and patient-level risk-stratification 
agreement of the TAVI models. This supports previous 
work that has demonstrated improvements in predictive 
performance of the EuroSCORE and STS models through 
the addition of frailty measures.11 12 39 40 Consequently, the 
heart team should consider frailty measures in addition to 
the multiple comorbidities that are reflected in existing 
risk scores, preferably by the inclusion of frailty directly 
into the risk prediction. We recommend that future itera-
tions of existing and new TAVI risk models should include 
markers of frailty/disability. Arguably, one should regard 
frailty as a spectrum, rather than a binary phenomenon; 
however, the sample size of the current study restricted 
our ability to subclassify KATZ and CSHA into their indi-
vidual components. Moreover, the marginal improve-
ment in predictive performance demonstrated after the 
inclusion of frailty/disability measures into existing TAVI 
CPMs, suggests that these measures cannot overcome the 
need to discover novel risk factors in this patient cohort, 
or the need to predict endpoints other than mortality 
(eg, readmission or quality of life).
Additionally, the quantification of TAVI risk by using 
subjective measures of frailty could be problematic in 
situations of low inter-rater reliability. The current study 
demonstrated large spatial variability in the proportion 
of TAVI procedures conducted on ‘frail’ patients, but 
the subjectivity of CSHA and KATZ means that we were 
unable to separate genuine spatial differences from 
systematic variation in how different teams define/record 
these measures. This provides further indication for the 
need to refine the assessment of frailty in TAVI patients, 
since the current methods were derived for different 
purposes.
study limitations
The strength of this study is that it is a large, contempo-
rary study, which has investigated the impact of frailty 
on outcomes and mortality prediction post-TAVI from a 
national perspective. However, several limitations need to 
be considered. First, only three subjective frailty measures 
were available, with objective frailty tests such as 6 min 
walk distance, grip strength or gait speed not recorded. 
Second, unmeasured confounders inherent in most 
observational studies potentially influence conclusions. 
Third, given that we could only analyse TAVI patients in 
2013/2014, this retrospective study was underpowered 
to investigate endpoints with small event rates such as 
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bleeding or myocardial infarction. As the volume of frailty 
data increases, future studies will be able to investigate 
such outcomes. Fourth, the current study had a signif-
icant proportion of patients who were removed due to 
missing frailty measures and/or missing life status, which 
could potentially bias the results. However, the proportion 
of missing data in other variables was low and we imple-
mented a multiple imputation procedure. Finally, given 
that this was a retrospective analysis of a national TAVI 
registry, we could not examine frailty in untreated patients 
with aortic stenosis, and neither could we compare the 
outcomes with patients treated through surgical aortic 
valve replacement. Thus, associations between frailty and 
the propensity for conservative treatment could not be 
explored, with corresponding potential for selection bias. 
Specifically, the analysis highlights potential measures to 
predict the expected outcomes after TAVI, but not the 
expected outcomes without TAVI.
COnClusIOns
Frailty and disability, as estimated by KATZ, CSHA and 
poor mobility, was significantly associated with mortality 
and morbidity after TAVI. The predictive performance 
and patient-level risk-stratification agreement were signifi-
cantly improved by updating existing TAVI CPMs to 
include measures of frailty/ADL dependency. Hence, 
physician-estimated frailty/disability measures could aid 
TAVI risk stratification, until scales that are more objec-
tive are routinely collected.
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